Hello and welcome back to a spooky Halloween edition of Endpoints Weekly! Sorry to all the candy corn lovers out there, but ...

Gilead pauses KITE-753 trials over ICANS; Agios' mitapivat PDUFA delayed; Acumen scraps sabirnetug; BMS drops BMS-986495; ...

AstraZeneca launches a restructuring to save $1.5B a year for R&D, beats Q3 sales forecasts and cuts several trials, ...

Eli Lil­ly once again dom­i­nat­ed rev­enue ex­pec­ta­tions, blow­ing past Wall Street’s es­ti­mates by about $2 bil­lion.

AstraZeneca's CEO Pascal Soriot & CFO Aradhana Sarin outline restructuring: cuts near Farxiga/Brilinta, reinvesting $1.5B in ...

Mer­ck’s head of R&D Dean Li be­lieves he’s out­foxed his com­pe­ti­tion for the next gen­er­a­tion of on­col­o­gy drugs, ...

Plowshare Therapies, led by Kevin Strauss, aims to develop a gene therapy for maple syrup urine disease, targeting ...

Vertex, Kindeva and Convatec pledge £1B+ for UK sites in Healey’s first Budget; Teva closes NJ plant; Regeneron extends ...

Aspen Neuroscience raises ~$141M and Bambusa ~$169M in Nasdaq IPOs, pushing 2026 biotech IPO haul to ~$8B across 29 deals.

Sanofi will keep launching new medicines across Europe under Trump’s MFN policy, possibly at higher prices, its CFO says.

AI agents are booking medical appointments & fighting insurance denials. Zocdoc welcomes agents; General Medicine designs ...

Anthropic buys Mithril Medicine, a one-person stealth biotech backed by Atlas whose founder ran the “Professor Oak” account ...